Cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) programs are often limited to centers in developed countries because of extensive requirements. We aimed to analyze efficacy ...
Real-world performance and clinical outcome of comprehensive genomic profiling of gastrointestinal tumors: High-volume, single-center experience. Unveiling prognosis and traits of dMMR/MSI-H gastric ...
InvestorsHub on MSN
Corcept shares soar after FDA approves relacorilant cancer treatment
Shares of Corcept Therapeutics (NASDAQ:CORT) surged about 40% on Wednesday after the U.S. Food and Drug Administration (FDA) approved relacorilant (Lifyorli) in combination with nab-paclitaxel for the ...
As cancer continues to rise across South Asia, global collaboration and advances in surgical oncology are offering new hope for patients.
FDA approval of Lifyorli plus nab-paclitaxel offers a new option for platinum-resistant epithelial ovarian cancer after 1 to 3 prior systemic regimens.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results